Evaluation of in vitro activity of ceftolozane-tazobactam compared to other antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients-Reference-Cited by-同舟云学术

Evaluation of in vitro activity of ceftolozane-tazobactam compared to other antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients

Published:2019-07 Issue:3 Volume:94 Page:297-303
ISSN:0732-8893
Container-title:Diagnostic Microbiology and Infectious Disease
language:en
Short-container-title:Diagnostic Microbiology and Infectious Disease

Author:

Gherardi Giovanni,Linardos Giulia,Pompilio Arianna,Fiscarelli Ersilia,Di Bonaventura Giovanni^ORCID

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference28 articles.

1. Pseudomonas bacteremia. Retrospective analysis of 410 episodes;Bodey;Arch Intern Med,1985

2. Clinical epidemiology of carbapenem-resistant gram-negative sepsis among hospitalized patients: shifting burden of disease?;Britt;Am J Infect Control,2018

3. Epidemiology and carbapenem resistance mechanisms of carbapenem non-susceptible Pseudomonas aeruginosa collected during 2009-2011 in 14 European and Mediterranean countries;Castanheira;J Antimicrob Chemother,2014

4. Different bacteriology and prognosis of thoracic empyemas between patients with chronic and end-stage renal disease;Chen;Chest,2007

5. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections;Chmiel;Ann Am Thorac Soc,2014

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antimicrobial susceptibility of ceftolozane-tazobactam against multidrug-resistant Pseudomonas aeruginosa isolates from Melbourne, Australia;Pathology;2023-08

2. Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review;Microorganisms;2023-07-13

3. Antimicrobial resistance of Pseudomonas aeruginosa in a cystic fibrosis population after introduction of a novel cephalosporin/β‐lactamase inhibitor combination;APMIS;2023-06-09

4. Evaluation of in-vitro susceptibility of ß-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil;Revista da Sociedade Brasileira de Medicina Tropical;2023

5. Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy;Journal of Global Antimicrobial Resistance;2022-09